REG - BiVictriX Therapcts. - BiVictriX AIM Rule 17 Notice

Bivictrix TherapeuticsAnnouncement

25/04/2022 09:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220425:nRSY1999Ja&default-theme=true

RNS Number : 1999J  BiVictriX Therapeutics PLC  25 April 2022

 

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company" or "the Group")

 

AIM Rule 17 Notice

 

Alderley Park, 25 April 2022 - BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a novel approach to develop next
generation cancer therapies using insights derived from frontline clinical
experience, announces that Iain Ross, Chairman of BiVictriX, has advised the
Company that further to the announcement of 17 December 2021 regarding Palla
Pharma Limited ("Palla Pharma"), of which he was a Non-Executive Director,
entering into voluntary administration, Palla Pharma has entered into
liquidation.  Iain Ross's resignation from the board of Palla Pharma was
accepted on 20 April 2022.

 

This announcement is made pursuant to Rule 17 and schedule 2, paragraph (g) of
the AIM Rules for Companies.

-Ends-

 

 

For more information, please contact:

 BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Iain Ross, Chairman                                    Email: info@bivictrix.com

 SP Angel Corporate Finance LLP (NOMAD and Broker)      Tel: +44 (0) 20 3470 0470
 David Hignell, Caroline Rowe (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)             Tel: +44 (0) 20 7886 2500

 Rupert Dearden, Freddy Crossley, Emma Earl

 Consilium Strategic Communications
 Mary-Jane Elliott, Melissa Gardiner, Genevieve Wilson  Tel: +44 (0) 20 3709 5700

                                                        Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst eliminating treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® therapeutics which are designed to selectively target
antigen co-expression fingerprints, or "twin antigens", on tumour cells, which
are largely absent from healthy cells. Whereas this concept has been validated
in a clinical diagnostic setting to support the diagnosis and monitoring of
haematological cancers, it has not yet been widely used in a therapeutic
setting.

 

BiVictriX has identified a diverse panel of novel cancer-specific "twin
antigens", across a broad range of solid tumour and haematological cancer
indications. The Company is using these novel "twin-antigens" to develop more
effective and safer therapeutics to target cancers that are expected to
constitute orphan indications and currently constitute areas of high unmet
medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUMPCUPPURA